MYC and B-cell non-Hodgkin lymphoma: In independent studies, Chen et al.[82] (using CYH33 against PI3Kα) and Zhang et al.[83] (using SAF-248 against PI3Kδ) evidenced that both compounds were effective in blocking B-cell lymphoma cell growth in vitro and in vivo, partly by causing the downregulation of MYC.